Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics (TVTX) drew investor attention on 4 August 2026 after reporting second quarter results that combined ...

Travere reported Filspari net product sales up year-on-year, with contribution from its Tiopronin products. Learn why TVTX ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand ...

Travere Therapeutics stock has delivered a very strong 341.0% return over the past five years, and the current valuation ...

(Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conf ...

Travere Therapeutics Inc. stock grades by Barron's. View TVTX fundamental and sentiment analysis powered by MarketGrader.

(SHOP) was up 25.3% in pre-market trading, and Travere Therapeutics Inc. (TVTX) was up 12.7%.

Travere Therapeutics Inc. TVTX shares surged 13.44% to $63.55 in after-hours trading on Tuesday after the biopharmaceutical ...

3 Under-the-Radar Healthcare Companies Travere Therapeutics (NASDAQ:TVTX) reported second-quarter results marked by record ...

Q2 reframed FILSPARI as a two-indication commercial story, with management emphasizing it was "the first quarter with FILSPARI commercially available across both IgA nephropathy and FSGS" (President, ...

Travere (TVTX) delivered earnings and revenue surprises of -164.29% and +10.16%, respectively, for the quarter ended June ...